Recent Updates — GCTK
The Nasdaq Stock Market LLC has determined to delist Glucotrack, Inc.'s common stock from its exchange because the company failed to satisfy the terms of a compliance exception. The Nasdaq Hearings Panel issued written notice on October 28, 2026, citing a closing bid price of $0.87 on October 14, 2026, which breached the requirement to maintain at least $1.00 through November 9, 2026. Trading in the company's shares will be suspended at the open on October 30, 2026. Nasdaq is expected to file a Form 25 to deregister the securities under Section 12(b) of the Securities Exchange Act. The company plans for its shares to begin trading on the OTCID Market tier of the OTC Markets Group. Glucotrack develops and markets medical devices for diabetes management.
Glucotrack filed a Certificate of Amendment to effect a one-for-two (1-for-2) reverse stock split of its common stock, which became effective on October 23, 2026. The transaction was approved by stockholders in August and reduced outstanding shares from approximately 2.4 million to roughly 1.18 million without changing par value or authorized share count. Options and warrants were proportionally adjusted. This filing also includes pro forma financial statements reflecting the July merger with Lokahi Therapeutics, which added $25.4 million in intangible assets and $15.6 million in goodwill, alongside approximately $7.95 million in bridge financing proceeds. Glucotrack operates in the medical technology sector, focusing on diabetes management solutions.
On October 22, 2026, Glucotrack entered into a private placement agreement to issue senior secured convertible promissory notes with an aggregate principal amount of $2,564,102 for gross proceeds of $2,000,000. The nine-month notes bear interest at 8% per annum and are convertible at a price equal to the lower of $0.6390 or 80% of the lowest daily volume-weighted average price over the preceding fifteen trading days. Concurrently, the company issued warrants to purchase 8,025,360 shares of common stock exercisable at $1.5975 per share for five years. Additionally, Glucotrack announced a 1-for-2 reverse stock split of its common stock, effective with the opening of trading on October 26, 2026, to help regain compliance with Nasdaq's minimum bid price requirement. The company operates Lōkahi Therapeutics, a biopharmaceutical platform focused on innovative therapeutic opportunities and continuous blood glucose monitoring technologies.
On October 13, 2026, Glucotrack entered into a Waiver Agreement with holders of existing warrants. The agreement waives restrictions on the company's ability to issue new common stock or equivalents for 90 days and removes exercise price adjustments under certain variable rate transactions. In exchange, Glucotrack issued new warrants exercisable at $7.50 per share for an aggregate of 406,198 shares. These new warrants expire in five years and require future stockholder approval to be exercisable. The company operates in the healthcare technology sector, developing digital health solutions.
Glucotrack completed its acquisition of Lokahi Therapeutics on July 14, 2026, issuing shares representing 90% of the combined equity to former Lokahi holders in a transaction valued at approximately $33.3 million. The deal includes $25.4 million in in-process research and development assets and $14.7 million in goodwill. Concurrently, Glucotrack raised $9.95 million through two rounds of senior secured convertible bridge notes ($4.45 million and $3.5 million) and a $2 million interim PIPE financing via prefunded warrants at $11.25 per share. The company also entered into a $50 million equity line of credit. Glucotrack develops continuous glucose monitoring technology for diabetes management.